Zydus Lifesciences on Sunday reported a largely flat consolidated net profit for the December quarter, weighed down by higher operating costs and a one-time Laboure-related provision, even as revenue recorded strong growth. The drugmaker posted a net profit of ₹1,042 crore in Q3FY26, marginally higher than ₹1,023 crore a year earlier. The performance was impacted by an ₹8.5 crore one-time provision linked to the implementation of new Laboure codes. Revenue from operations rose 30.3% year-on-year to ₹6,780 crore, supported by steady growth in the India business, a stronger US portfolio and robust international sales. EBITDA for the quarter increased 31% to ₹1,816 crore, with margins improving to 26.5%.
Zydus’ India business grew 13% YoY, driven by chronic therapies, while its US business rose 16.4% to ₹2,804 crore. The international segment posted a strong 38% growth, reflecting demand across markets.
The company said its strategic focus on portfolio expansion, biosimilars and disciplined business development continues to support long-term growth.
Zydus Lifesciences Q3 Profit Flat on One-Time Costs; Revenue Jumps 30% YoY
